Board of Directors


Mark Agne was at Goldman Sachs from 1997 until his retirement in 2016. He was made a partner in 2006 and held various senior leadership roles in Asia, including head of Asia Equity Trading and Head of Securities (Equities and Fixed Income), Japan. He was a member of Asian Operating Committee, Asian Risk Committee, Asian Operational Risk Committee, and Asian Suitability Committee. Mr. Agne serves on the boards of the Nature Conservancy, Hawai‘i and the Hawai‘i Community Foundation.


James Marks is Chief of Anesthesia at San Francisco General Hospital; Professor of Anesthesia at the University of California, San Francisco (UCSF); and Vice Chairman of the Department of Anesthesia and Perioperative Care at UCSF. A world-recognized pioneer in the fields of antibody and protein engineering, Dr. Marks is a practicing anesthesiologist and intensivist with clinical interests in trauma anesthesia and critical care and research interests in the area of antibody and protein engineering. He is board-certified in Internal Medicine, Anesthesia, and Critical Care Medicine. Prior to becoming Chief of Anesthesia, Dr. Marks was the Medical Director of the Trauma ICU at SFGH. He is an elected member of the Institute of Medicine of the National Academy of Sciences. Dr. Marks received his MD from UCSF and a PhD in Molecular Biology from the Medical Research Council (MRC) in Cambridge, England. He completed residencies in Internal Medicine and Anesthesia as well as a fellowship in Critical Care Medicine, all at UCSF.


Jeff Munsie is General Counsel and Head of Corporate Operations for Merrimack Pharmaceuticals, which he has advised and led through a number of transformative events including private and public financing, business development transactions, FDA approval and commercialization, and the recent sale of its commercial drug, ONIVYDE®. Previously, he served as outside Counsel in the corporate department at the law firm, WilmerHale. Mr. Munsie holds an AB in Engineering and Environmental Science from Dartmouth College and a JD from Harvard Law School.


Thomas Murtagh is a Co-Founder of Clarion Healthcare LLC, a boutique life sciences strategy and organizational consultancy based in Boston, MA. His main areas of practice include:

  • Architecting innovative product profiles that will meet patient needs 5-10 years in the future
  • Strategic trade-off and investments decisions for pipeline assets (e.g., indication selection and prioritization)
  • Defining investment requirements to support effective commercialization in the era of evidence-based medicine
  • Anticipating new organizational requirements to support the rapidly evolving healthcare system and fundamental changes in the model for bringing therapeutics to patients

Prior to founding Clarion in 2003, Mr. Murtagh was a Vice President in Braun Consulting’s Healthcare Practice, a former member of the management team at Vertex Partners, and a former member of Arthur D. Little’s Healthcare team. He holds an MBA in Finance from the University of Chicago and an AB from Dartmouth College.


Ulrik Nielsen is President and co-founder of Torque, an immuno-oncology company. He was previously a founder of Merrimack, where he served as Chief Scientific Officer until 2015 and remains on the board of directors. At Merrimack, Dr. Nielsen was responsible for R&D and the early phases of clinical development. Prior to joining Merrimack, he was a postdoctoral fellow at Massachusetts Institute of Technology, where he researched the interface among biology, engineering, and computational biology. Dr. Nielsen received MS and PhD degrees in Molecular Biology from the University of Copenhagen and trained at the University of California, San Francisco. He has undertaken extensive executive business education, including education at Harvard Business School (PLD graduate).